150 related articles for article (PubMed ID: 31984843)
1. Severe mercaptopurine-induced hypoglycemia in acute lymphoblastic leukemia.
Rebelo A; Oliveira J; Sousa C
Pediatr Hematol Oncol; 2020 Apr; 37(3):245-247. PubMed ID: 31984843
[TBL] [Abstract][Full Text] [Related]
2. Severe Recurrent Nocturnal Hypoglycemia During Chemotherapy With 6-mercaptopurine in 2 Children With Acute Lymphoblastic Leukemia.
Albiroty K; Al Sabahi A
J Pediatr Hematol Oncol; 2023 Apr; 45(3):162-163. PubMed ID: 36706266
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia.
Zhang M; Bostrom B
F1000Res; 2019; 8():176. PubMed ID: 30828444
[TBL] [Abstract][Full Text] [Related]
4. Severe hypoglycemic seizures in a child receiving 6-mercaptopurine.
El-Bitar MK; Muwakkit SA; Dabbagh O
J Pediatr Hematol Oncol; 2011 Mar; 33(2):e75-6. PubMed ID: 21343747
[TBL] [Abstract][Full Text] [Related]
5. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoma during maintenance therapy.
Barone T; Dandekar S; McKeone D; Mulieri K
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1987. PubMed ID: 38351548
[TBL] [Abstract][Full Text] [Related]
6. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
7. Continuous glucose monitoring: a valuable monitoring tool for management of hypoglycemia during chemotherapy for acute lymphoblastic leukemia.
Visavachaipan N; Aledo A; Franklin BH; Brar PC
Diabetes Technol Ther; 2013 Jan; 15(1):97-100. PubMed ID: 23145966
[TBL] [Abstract][Full Text] [Related]
8. Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia.
Halonen P; Salo MK; Mäkipernaa A
J Pediatr; 2001 Mar; 138(3):428-31. PubMed ID: 11241057
[TBL] [Abstract][Full Text] [Related]
9. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
[TBL] [Abstract][Full Text] [Related]
10. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
11. Intracellular pharmacology and biochemistry of methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; Bökkerink JP; Trijbels JM; vd Heijden MA; De Abreu RA
Adv Exp Med Biol; 1994; 370():115-8. PubMed ID: 7660872
[No Abstract] [Full Text] [Related]
12. Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report.
McNerney KO; Vasquez JC; Kent MW; McNamara JM
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e454-e455. PubMed ID: 28085749
[TBL] [Abstract][Full Text] [Related]
13. Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites.
Miller MB; Brackett J; Schafer ES; Rau RE
Pediatr Blood Cancer; 2019 Apr; 66(4):e27577. PubMed ID: 30548777
[TBL] [Abstract][Full Text] [Related]
14. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
15. Profound Hypoglycemia and High Anion Gap Metabolic Acidosis in a Pediatric Leukemic Patient Receiving 6-Mercaptopurine.
O'Shea M; Kuhn A; Creo AL; Kohorst M; Ferdjallah A
Children (Basel); 2024 Jan; 11(2):. PubMed ID: 38397272
[TBL] [Abstract][Full Text] [Related]
16. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
Ziino O; Russo D; Orlando MA; Benigno V; Locatelli F; Aricò M
Med Pediatr Oncol; 2002 Jul; 39(1):32-4. PubMed ID: 12116076
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia.
Schmiegelow K
Pediatr Hematol Oncol; 1991; 8(4):301-12. PubMed ID: 1782110
[TBL] [Abstract][Full Text] [Related]
19. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Evans WE; Horner M; Chu YQ; Kalwinsky D; Roberts WM
J Pediatr; 1991 Dec; 119(6):985-9. PubMed ID: 1960624
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic hypoglycemia: an unusual side effect of oral purine analogues for treatment of ALL.
Bay A; Oner AF; Cesur Y; Dogan M; Etlik O; Sanli F
Pediatr Blood Cancer; 2006 Sep; 47(3):330-1. PubMed ID: 16047348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
